rBV A/B

BIOLOGICAL5 trials

Sponsors

DynPort Vaccine Company LLC, A GDIT Company, California Department of Public Health

Conditions

BotulismRECOMBINANT BOTULINUM VACCINE A/B

Phase 1

Study to Evaluate the Safety, Tolerability and Immunogenicity of Recombinant Botulinum Vaccine A/B in Healthy Adults

CompletedNCT00098098

DynPort Vaccine Company LLC, A GDIT CompanyRECOMBINANT BOTULINUM VACCINE A/B

Start: 2004-08-31End: 2005-08-31Target: 44Updated: 2012-08-23

Phase 2

Safety, Tolerability, and Immunogenicity Study of Investigational Recombinant Botulinum Vaccine A/B (rBV A/B) in Volunteers Previously Immunized With Investigational Pentavalent Botulinum Toxoid

CompletedNCT01701999

California Department of Public HealthBotulism

Start: 2013-02-28End: 2015-10-31Updated: 2017-05-16

Tolerability and Immunogenicity of rBV A/B for the Production of BabyBIG®

CompletedNCT03676634

California Department of Public HealthBotulism

Start: 2019-03-07End: 2020-07-03Updated: 2021-10-19

Tolerability and Immunogenicity of a Single 40-ug Dose of rBV A/B for the Production of BabyBIG®

CompletedNCT06112834

California Department of Public HealthBotulism

Start: 2024-07-09End: 2025-06-02Updated: 2026-07-30

Phase 3

Phase 3, Randomized, Safety, Lot Consistency and Clinical Benefit Study of Recombinant Botulinum Vaccine A/B

WithdrawnNCT01940315

DynPort Vaccine Company LLC, A GDIT CompanyBotulism

Start: 2017-10-31End: 2019-09-30Updated: 2018-12-04

Related Papers

Safety and immunogenicity of investigational recombinant botulinum vaccine, rBV A/B, in volunteers with pre-existing botulinum toxoid immunity.

2018-02-2125 citations